{
    "clinical_study": {
        "@rank": "151495", 
        "acronym": "TRICIDIA", 
        "arm_group": [
            {
                "arm_group_label": "Intensified multiple injections", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Pumps", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open multicentre, randomized study to compare two treatment arms. One arm called\n      \"intensification of multiple injections\" in which the patient will receive one supplementary\n      injection of LEVEMIR\u00ae: that is to say 5 injections per day, and an arm called \"continuous\n      insulin infusion\" via an external pump with APIDRA\u00ae.\n\n      In the pump arm: a favorable effect in terms of improved insulin sensitivity, improved\n      metabolic equilibrium, a decrease in the area under the baseline and prandial hyperglycemia\n      curve noted during the continuous glycemia recording; an improvement in quality of life\n      compared with treatment using multiple injections."
        }, 
        "brief_title": "Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes", 
        "condition": "Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persons who have provided written informed consent\n\n          -  Age > 18 years\n\n          -  Patients with type 2 diabetes treated with insulin using a basal / bolus strategy for\n             at least 6 months\n\n          -  Doses of insulin > 0.7 U / Kg / d\n\n          -  HbA1c \u2265 7.5 %\n\n          -  Without OAD for at least 4 weeks (sulfamides, Incretines, glinides, acarbose) except\n             Metformin\n\n          -  BMI \u2265 28.5 kg / m2\n\n          -  Diabetes diagnosed for at least 10 years\n\n          -  Patients able to monitor themselves and manage an insulin pump.\n\n        Exclusion Criteria:\n\n          -  Patients treated with glitazones during the 3 months preceding inclusion\n\n          -  Patients with proliferative ischemic retinopathy not treated by laser\n\n          -  BMI < 28.5 kg / m2\n\n          -  Presence of implantable material ( CI MRI )\n\n          -  Pacemaker ( CI MRI )\n\n          -  Pregnancy, breast feeding\n\n          -  Medically significant physical or psychiatric inability, patients under guardianship\n             or wards of court\n\n          -  The practice of violent sports\n\n          -  Poor conditions of hygiene\n\n          -  Professional environment of extreme cold or heat."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048189", 
            "org_study_id": "RUDONI PARI 2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intensified multiple injections", 
                "intervention_name": "LEVEMIR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pumps", 
                "intervention_name": "APIDRA", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Alfred PENFORMIS"
                }, 
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25000"
                    }, 
                    "name": "CHU de Besancon"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sabine.rudoni@chu-dijon.fr", 
                    "last_name": "Sabine BAILLOT-RUDONI", 
                    "phone": "3.80.29.34.53", 
                    "phone_ext": "+33"
                }, 
                "contact_backup": {
                    "email": "isabelle.simoneau-robin@chu-dijon.fr", 
                    "last_name": "Isabelle SIMONEAU-ROBIN", 
                    "phone": "3 80 29 33 32", 
                    "phone_ext": "+33"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "CHU de Dijon"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment", 
        "overall_contact": {
            "email": "sabine.rudoni@chu-dijon.fr", 
            "last_name": "Sabine BAILLOT-RUDONI", 
            "phone": "3.80.29.34.53", 
            "phone_ext": "+33"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mixed measurement of insulin secretion and insulin resistance", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline insulin secretion and insuline resistance at 6 month after starting the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048189"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Decrease in the time spent in baseline and prandial hyperglycemia", 
            "safety_issue": "No", 
            "time_frame": "During the 6 months following initiation of the treatment"
        }, 
        "source": "Centre Hospitalier Universitaire Dijon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Dijon", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2012"
    }
}